Nasdaq News

(RTTNews) - SciBase Holding AB announced that its skin cancer assessment technology, Nevisense, has received its first positive medical coverage policy from Highmark Blue Cross Blue Shield, marking a significant reimbursement milestone for the company's U.S. business.

(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced the commercial launch of Imcivree (setmelanotide) in Japan for acquired hypothalamic obesity, following its inclusion on the country's National Health Insurance (NHI) drug price list.

Key PointsNextEra's dividend appears sustainable based on its projected earnings.

(RTTNews) - Asian stocks ended mostly lower on Wednesday, even as pressure on tech stocks eased and dovish Fed remarks spurred expectations that the U.S. Federal Reserve may not need to raise interest rates aggressively next year.

(RTTNews) - Insilico Medicine (3696.HK), a biotechnology company that integrates AI and automation to accelerate drug discovery, has nominated a new experimental drug candidate, ISM9546, designed with generative AI to target autoimmune diseases such as inflammatory bowel disease

Key PointsNew CEO John Ternus plans to take a more hands-on role with design.

Key PointsThe summer stock market was livelier than many expected it to be.

Key PointsThe Bureau of Labor Statistics will release the September inflation report today, Oct. 14.

Key PointsBuffett warned 25 years ago about a specific stock market scenario.

Key PointsA dozen cryptocurrencies have posted returns of 100% or higher during the past three months.

Key PointsMicron has now inked a total of 26 strategic customer agreements that provide long-term pricing frameworks, up from 16 three months ago.

(RTTNews) - Nxera Pharma Co., Ltd. (4565.T), a technology-powered biopharmaceutical company, on Wednesday announced an exclusive licensing, supply and commercialization agreement with Synmosa Biopharma Corp. (4114.TWO).

Key PointsThe Vanguard Morningstar Value ETF has gained around 18% in 2026, topping the growth fund's 13%.

Key PointsNike's sales fell 4% in the latest fiscal quarter, with Greater China down 22%.

(RTTNews) - On Wednesday, Orum Therapeutics, Inc. (475830.KQ), a biotechnology company developing degrader-antibody conjugates (DACs), announced that the first patient has been dosed in a Phase 1 trial evaluating ORM-1153 in patients with relapsed or refractory acute myeloid leuk

(RTTNews) - Pharming Group N.V. (PHAR) reported positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies associated with altered PI3Kdelta signaling.

Key PointsMicron's annual report shows no customer made up 10% or more of its revenue in fiscal 2026.

(RTTNews) - AgomAb Therapeutics NV (AGMB) announced that the first patient has been dosed in NOV-ERA, a global Phase 2b trial evaluating Ontunisertib in patients with symptomatic fibrostenosing Crohn's disease (FSCD).

(RTTNews) - Galderma (GALD.SW), a dermatology company, announced that it has signed an agreement to acquire ZO Skin Health, a skincare brand, for an enterprise value of $1.5 billion in an all-cash transaction.

(RTTNews) - On Wednesday, Pharming Group N.V. (PHAR) announced positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation linked to altered PI3Kdelta signa